Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease

• DOI: 10.2217/cer-2019-0101
• Publication Date: 2019-09-27T10:25:20Z
• Authors: Swetha R Palli; Ami R Buikema; Mary DuCharme; Monica Frazer; Shuchita Kaila; Timothy Juday
• Keywords: Muscarinic antagonist; Fluticasone propionate

Aim: To compare health plan-paid costs, exacerbations and pneumonia outcomes for patients with chronic obstructive pulmonary disease (COPD) initiating combination tiotropium olodaterol (TIO + OLO) versus triple therapy (TT: long-acting muscarinic antagonist β 2 agonists inhaled corticosteroid). Patients & methods: COPD TIO OLO or TT between 1 January 2014 30 June 2016 were identified from a managed care Medicare database balanced baseline characteristics using inverse probability of treatment weighting before assessment outcomes. Results: Annual COPD-related all-cause costs US$4118 (35%) US$5384 (23%) lower (both p ≤ 0.001). had nearly half the severe (8.3 vs 15.5%; = 0.014) was also less common (18.9 30.9%; < Conclusion: associated improved economic TT.